This is a mouse model, so treatment toxicity as always remains a question mark in humans. Additionally, protein degraders like SD36 are very new, I don’t think any are FDA approved at this point, and figuring out e.g. dosing for human clinical trials will require more research on e.g. bioavailability, stability, etc. in humans.

...in mice

Please do not get your science reporting from the NYPost. 99% chance it's some random press release fetched when an editor says "hey let's try to do a feel good science story" and it will not be placed into context of what the actual chances for success are; that only comes from Phase 3 clinical trials in humans.

And often the first trials are not very impressive, just barely enough to get approval, and then slowly more effective use of the treatment is found through more trials later on.

It's a slow pace of discovery, with few "holy shit this is amazing moments" that are recognizable to anyone who's not in the thick of knowing what typical treatments and outcomes are for a specific type of cancer.

Maybe the NYPost is trying to turn a corner towards doing serious journalism, but this is not it. The first time they mention KRAS it has a typo as KRS which tells you the author knows jack shit about anything related to the topic. That's not a typo that survives a basic proofreading. KRAS is a major player in cancer, not just pancreatic cancer.